CTLA4 and non-small cell lung carcinoma: Conforti and colleagues demonstrated that male patients with advanced melanoma and non-small cell lung cancer (NSCLC) obtained a significantly better efficacy from anti-CTLA4 or anti-PD-1 monotherapy than female patients [3].